Gaudium IVF Introduces AI-Led Infertility Treatment with Embryology Systems in India

The initiative includes the deployment of AI-driven tools such as SiD (Sperm Identification Device) and ERICA (Embryo Ranking Intelligent Classification Assistant), aimed at improving decision-making during key stages of the IVF process.

Gaudium IVF has introduced artificial intelligence (AI)-led infertility treatment in India, integrating advanced embryology systems into clinical practice to enhance IVF outcomes. The development comes shortly after the company became the country’s first publicly listed IVF chain.

The initiative includes the deployment of AI-driven tools such as SiD (Sperm Identification Device) and ERICA (Embryo Ranking Intelligent Classification Assistant), aimed at improving decision-making during key stages of the IVF process. The systems have been introduced as part of a collaboration with IVF 2.0, a UK-based embryology innovation organization founded by Dr Jacques Cohen and Dr Alejandro Chave.

The integration was formally inaugurated by Union Minister Nitin Jairam Gadkari, who highlighted the role of advanced technologies in driving innovation across sectors.

According to the company, SiD uses AI to analyze sperm movement parameters and identify viable sperm for fertilization, to improve blastocyst quality. ERICA, on the other hand, evaluates static images of embryos based on morphological and developmental characteristics, providing data-driven rankings to support embryo selection.

These tools are designed to assist embryologists by introducing consistency and reducing variability in clinical decision-making. The systems are non-invasive and aim to standardize processes that are traditionally dependent on manual assessment.

Dr Manika Khanna, Chairperson and Managing Director of Gaudium IVF, stated that integrating AI into fertility care is expected to improve treatment precision and predictability. She added that the collaboration with IVF 2.0 enables access to globally developed embryology technologies within the Indian clinical ecosystem.

Giles Palmer, Clinical Scientist at IVF 2.0, noted that the partnership allows the deployment of AI-driven embryology tools in a high-growth market, focusing on measurable clinical outcomes.

Early clinical observations cited by the company indicate improvements in fertilization rates and blastocyst development. The use of AI in these stages may also reduce the need for repeated IVF cycles, potentially lowering the physical and financial burden on patients.

The introduction of AI-based embryology tools reflects a broader shift toward technology-enabled precision in reproductive medicine, particularly in high-demand fertility care markets like India.

Stay tuned for more such updates on Digital Health News